Systematically exploring repurposing effects of antihypertensives.

With availability of voluminous sets of observational data, an empirical paradigm to screen for drug repurposing opportunities (i.e., beneficial effects of drugs on nonindicated outcomes) is feasible. In this article, we use a linked claims and electronic health record database to comprehensively explore repurposing effects of antihypertensive drugs. We follow a target trial emulation framework for causal inference to emulate randomized controlled trials estimating confounding adjusted effects of antihypertensives on each of 262 outcomes of interest. We then fit hierarchical models to the results as a form of postprocessing to account for multiple comparisons and to sift through the results in a principled way. Our motivation is twofold. We seek both to surface genuinely intriguing drug repurposing opportunities and to elucidate through a real application some study design decisions and potential biases that arise in this context. © 2022 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.

Citation

Zach Shahn, Phoebe Spear, Helen Lu, Sharon Jiang, Suki Zhang, Neil Deshmukh, Shenbo Xu, Kenney Ng, Roy Welsch, Stan Finkelstein. Systematically exploring repurposing effects of antihypertensives. Pharmacoepidemiology and drug safety. 2022 Jun 21;31(9):944-952

Mesh Tags

Substances

PMID: 35689299

search → result